C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 145, Issue 1-2, 2003, Pages 135-138

  Miyagishi, Ryuji ^a   Niino, Masaaki ^a   Fukazawa, Toshiyuki ^b   Yabe, Ichiro ^a   Kikuchi, Seiji ^a   Tashiro, Kunio ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hokuyukai Neurology Hospital   (Japan)

Author keywords

CCR2; Chemokine; Japanese; Multiple sclerosis; Polymorphism; Susceptibility gene

Indexed keywords

CHEMOKINE RECEPTOR CCR2; HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ETHNIC GROUP; FEMALE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL MODEL;

EID: 0344872707     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.09.003     Document Type: Article

References (29)

1. Barcellos L.F., Schito A.M., Rimmler J.B., Vittinghoff E., Shih A., Lincoln R., Callier S., Elkins M.K., Goodkin D.E., Haines J.L., Pericak-Vance M.A., Hauser S.L., Oksenberg J.R. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics. 51:2000;281-288.
2. Bennetts B.H., Teutsch S.M., Buhler M.M., Heard R.N.S., Stewart G.J. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 58:1997;52-59.
3. Charo I.F. CCR2: from cloning to the creation of knockout mice. Chem. Immunol. 72:1999;30-41.
4. Favorova O.O., Andreewski T.V., Boiko A.N., Sudomoina M.A., Alekseenkov A.D., Kulakova O.G., Slanova A.V., Gusev E.I. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology. 59:2002;1652-1655.
5. Fife B.T., Huffnagle G.B., Kuziel W.A., Karpus W.J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:2000;899-905.
6. Fukazawa T., Miyasaka K., Tashiro K., Hamada T., Moriwaka F., Yanagihara T., Hamada K. MRI findings of multiple sclerosis with acute transverse myelopathy. J. Neurol. Sci. 110:1992;27-31.
7. Fukazawa T., Yamasaki K., Ito H., Kikuchi S., Minohara M., Horiuchi I., Tsukishima E., Sasaki H., Hamada T., Nishimura Y., Tashiro K., Kira J. Both the HLA-DPB1 and-DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens. 55:2000;199-205.
8. Izikson L., Klein R.S., Charo I.F., Weiner H.L., Luster A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR) 2. J. Exp. Med. 192:2000;1075-1080.
9. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
10. Lee B., Doranz B.J., Rana S., Yi Y., Mellado M., Frade J.M., Martinez A.-C., O'Brien S.J., Dean M., Collman R.G., Doms R.W. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J. Virol. 72:1998;7450-7458.
11. Mahad D.J., Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 15:2003;23-32.
12. Mariani R., Wong S., Mulder L.C., Wilkinson D.A., Reinhart A.L., LaRosa G., Nibbs R., O'Brien T.R., Michael N.L., Connor R.I., Macdonald M., Busch M., Koup R.A., Landau N.R. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J. Virol. 73:1999;2450-2459.
13. Martinson J.J., Chapman N.H., Rees D.C., Liu Y.T., Clegg J.B. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16:1997;100-103.
14. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:2001;121-127.
15. Mellado M., Rodriguez-Frade J.M., Vila-Coro A.J., de Ana A.M., Martinez-A C. Chemokine control of HIV-1 infection. Nature. 400:1999;723-724.
16. Misu T., Onodera H., Fujihara K., Matsushima K., Yoshie O., Okita N., Takase S., Itoyama Y. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J. Neuroimmunol. 114:2001;207-212.
17. Miyagishi R., Kikuchi S., Takayama C., Inoue Y., Tashiro K. Identification of cell types producing RANTES, MIP-1α and MIP-1β in rat experimental autoimmune encephalomyelitis by in situ hybridization. J. Neuroimmunol. 77:1997;17-26.
18. Niino M., Fukazawa T., Yabe I., Kikuchi S., Sasaki H., Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J. Neurol. Sci. 177:2000;65-71.
19. Niino M., Kikuchi S., Fukazawa T., Yabe I., Sasaki H., Tashiro K. Heat shock protein 70 gene polymorphism in Japanese patients with multiple sclerosis. Tissue Antigens. 58:2001;93-96.
20. Niino M., Kikuchi S., Fukazawa T., Yabe I., Sasaki H., Tashiro K. Genetic polymorphisms of IL-1β and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 118:2001;295-299.
21. Niino M., Kikuchi S., Fukazawa T., Miyagishi R., Yabe I., Tashiro K. An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. BMC Neurol. 21:2002;8.
22. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J. Neuroimmunol. 127:2002;177-179.
23. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 136:2003;125-129.
24. Simpson J., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84:1998;238-249.
25. Simpson J., Rezaie P., Newcombe J., Cuzner M.L., Male D.M., Nicola Woodroofe M.N. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J. Neuroimmunol. 108:2000;192-200.
26. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., Goedert J.J., O'Brien T.R., Jacobson L.P., Kaslow R., Buchbinder S., Vittinghoff E., Vlahov D., Hoots K., Hilgartner M.W., O'Brien S.J. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science. 277:1997;959-965.
27. Sorensen T.L., Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology. 57:2001;1371-1376.
28. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:1999;807-815.
29. Youssef S., Wildbaum G., Maor G., Lanir N., Gour-Lavie A., Grabie N., Karin N. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161:1998;3870-3879.